Non-Invasive Prenatal Testing Market to Set Phenomenal Growth in Key Regions by 2026

BRUSSELS - Oct. 13, 2022 - PRLog -- Non-invasive prenatal testing (NIPT), is a method of determining the risk of whether the fetus of the mother will be born with specific genetic disorders. NIPT is a safe and extremely effective way of screening for conditions such as Down syndrome, Edwards syndrome, Patau syndrome, monosomy X, and Turner syndrome.

Currently, massive parallel sequencing (MPS) technology and the single-nucleotide polymorphism (SNP) based method are the two types of NIPT methods that are commercially accessible.

Rising acceptance of cell-free DNA screening, advantageous reimbursement policies for average and low-risk pregnancies, high risk of chromosomal abnormalities with increasing maternal age, and increasing prevalence of genetic and congenital disorders are some of the main factors driving the global non-invasive prenatal testing market.

Arrival of Advanced Technologies for NIPT Products
The advent of next-generation sequencing technology has enabled the sequencing of fetal DNA fragments that can be assembled into a full genetic map, allowing the fetal genome to be scanned prenatally and non-invasively. Advances in molecular technologies and the discovery of cell-free fetal DNA in maternal plasma have also led to novel screening methods for fetal chromosomal aneuploidies.

The market now offers a variety of NIPT tests including Panorama, Vistara, MaterniT GENOME, Harmony Test, among others which help in the screening of chromosomal abnormalities developing in the fetus.

Additionally, several developments have been made to impact the quality of care for expectant mothers such as:

• In January 2022, QIAGEN entered into collaborations with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN's dPCR franchise.
• In June 2021, Illumina and Next-generation Genomic Thailand announced the launch of next-generation sequencing (NGS)-based VeriSeq NIPT Solution v2 in the country which helps to detect anomalies missed by targeted assays.

"Prenatal care is a dynamic and continuously evolving field. Development in new molecular technologies and the discovery of cell-free fetal DNA are fueling groundbreaking advancements to improve care for mother and child and to offer parents reproductive options." - Senior Director, Head of Research & Product Development, Sequencing & Array-based Company, United States

Explore Premium Report on Non-Invasive Prenatal Testing Market @ https://meditechinsights.com/non-invasive-prenatal-testing-market/